Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.140 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,288
Open	2.140
Bid (Size)	2.140 (300)
Ask (Size)	2.160 (300)
Prev. Close	2.140
Today's Range	2.140 - 2.140
52wk Range	1.830 - 4.270
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

December 29, 2025

From ImmunityBio, Inc.

Via Business Wire

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

December 16, 2025

From ImmunityBio, Inc.

Via Business Wire

Performance

YTD	+5.9%	+5.9%
1 Month	-5.3%	-5.3%
3 Month	-14.4%	-14.4%
6 Month	-21.0%	-21.0%
1 Year	-22.5%	-22.5%

More News

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

December 12, 2025

From ImmunityBio

Via Business Wire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 28, 2025

Via Chartmill

A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know ↗

November 19, 2025

Via The Motley Fool

Heights Capital Walks From Archer Aviation: What It Means for Investors ↗

November 19, 2025

Via The Motley Fool

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals ↗

September 17, 2025

Via Stocktwits

Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean. ↗

November 19, 2025

Via The Motley Fool

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

November 13, 2025

From ImmunityBio, Inc.

Via Business Wire

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

November 04, 2025

From ImmunityBio, Inc.

Via Business Wire

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗

October 22, 2025

Via Benzinga

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Via MarketBeat

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts ↗

September 12, 2025

Via Stocktwits

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

September 08, 2025

From ImmunityBio, Inc.

Via Business Wire

What's Going On With ImmunityBio Shares Tuesday? ↗

August 26, 2025

Via Benzinga

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

August 26, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

August 19, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

August 13, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

August 11, 2025

From ImmunityBio, Inc.

Via Business Wire

IBRX Sales Soar 2,540% ↗

August 05, 2025

Via The Motley Fool

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

August 05, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

July 25, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

July 25, 2025

From ImmunityBio, Inc.

Via Business Wire

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper ↗

July 22, 2025

Via Benzinga

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via Investor Brand Network

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 2.140

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 01/06/26 04:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 837.07M

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 837M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.